Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial
The Journal of Clinical Endocrinology & Metabolism · 17.03.2025 · 110 (4) · 951-960
DOI: 10.1210/clinem/dgae693 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 08.10.2024. Verfasst von Bart L Clarke und 19 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology, Mayo Clinic E18-A, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Hypoparathyroidism, Parathyroid Hormone. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ascendis Pharma Bone Diseases A/S, Hellerup, Denmark.
Abstract (Originalsprache)
Context
Conventional therapy for hypoparathyroidism aims to alleviate symptoms of hypocalcemia but does not address insufficient parathyroid hormone (PTH) levels.
Objective
Assess the long-term efficacy and safety of TransCon PTH (palopegteriparatide) for hypoparathyroidism.
Design
Phase 3 trial with a 26-week, double-blind, placebo-controlled period followed by a 156-week, open-label extension (OLE).
Setting
Twenty-one sites across North America and Europe.
Participants
A total of 82 adults with hypoparathyroidism were randomized and received study drug and 78 completed week 52. Intervention(s) All OLE participants received TransCon PTH administered once daily. Main Outcome Measure(s) Multicomponent efficacy endpoint: proportion of participants at week 52 who achieved normal serum calcium (8.3-10.6 mg/dL) and independence from conventional therapy (≤600 mg/day of elemental calcium and no active vitamin D). Other efficacy endpoints included patient-reported outcomes and bone mineral density. Safety was assessed by 24-hour urine calcium and treatment-emergent adverse events.
Results
At week 52, 81% (63/78) met the multicomponent efficacy endpoint, 95% (74/78) achieved independence from conventional therapy, and none required active vitamin D. Patient-reported outcomes showed sustained improvements in quality of life, physical functioning, and well-being. Mean bone mineral density Z-scores decreased toward age- and sex-matched norms from baseline to week 52. Mean (SD) 24-hour urine calcium excretion decreased from 376 (168) mg/day at baseline to 195 (114) mg/day at week 52. Most treatment-emergent adverse events were mild or moderate and none led to trial discontinuation during the OLE.
Conclusion
At week 52 of the PaTHway trial, TransCon PTH showed sustained efficacy, safety, and tolerability in adults with hypoparathyroidism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology, Mayo Clinic E18-A, Rochester, MN 55905, USA.
- Endocrinology, Metabolism, and Geriatrics, McMaster University, Hamilton, ON L8S 4L8, Canada.
- Endocrinology, Columbia University, New York, NY 10032, USA.
- Internal Medicine and Endocrinology, Rigshospitalet, 2100 Copenhagen, Denmark.
- Endocrinology, Diabetes, and Metabolism, University of Chicago, Chicago, IL 60637, USA.
- Endocrinology, VA Medical Center, University of California, San Francisco, San Francisco, CA 94143, USA.
ORCID-Profile: Dolores M Shoback, Claudia Gagnon, Andrea Palermo, Filomena Cetani, Aimee D Shu, Lars Rejnmark
Förderung
- Ascendis Pharma Bone Diseases A/S, Hellerup, Denmark
Zitieren
APA
Clarke, B. L., Khan, A. A., Rubin, M. R., Schwarz, P., Vokes, T., Shoback, D. M., Gagnon, C., Palermo, A., Abbott, L. G., Hofbauer, L. C., Kohlmeier, L., Cetani, F., Pihl, S., An, X., Smith, A. R., Lai, B., Ukena, J., Sibley, C. T., Shu, A. D., & Rejnmark, L. (2025). Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. The Journal of Clinical Endocrinology & Metabolism, 110(4), 951-960. https://doi.org/10.1210/clinem/dgae693
Vancouver
Clarke BL, Khan AA, Rubin MR, Schwarz P, Vokes T, Shoback DM, et al. Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. The Journal of Clinical Endocrinology & Metabolism. 2025;110(4):951-960. doi:10.1210/clinem/dgae693
BibTeX
@article{Clarke2025,
author = {Clarke, Bart L and Khan, Aliya A and Rubin, Mishaela R and Schwarz, Peter and Vokes, Tamara and Shoback, Dolores M and Gagnon, Claudia and Palermo, Andrea and Abbott, Lisa G and Hofbauer, Lorenz C and Kohlmeier, Lynn and Cetani, Filomena and Pihl, Susanne and An, Xuebei and Smith, Alden R and Lai, Bryant and Ukena, Jenny and Sibley, Christopher T and Shu, Aimee D and Rejnmark, Lars},
title = {Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {4},
pages = {951--960},
doi = {10.1210/clinem/dgae693}
}
EUVIMED